<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983682</url>
  </required_header>
  <id_info>
    <org_study_id>1000052256</org_study_id>
    <nct_id>NCT02983682</nct_id>
  </id_info>
  <brief_title>Lidocaine Infusions for Chronic Pain in Children</brief_title>
  <official_title>A Pilot Study of the Effectiveness of Lidocaine Infusions for the Management of Chronic Pain in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of lidocaine in the management of chronic&#xD;
      pain in children. All participants will receive lidocaine infusion and severity of pain and&#xD;
      degree of chronic-pain related disability will be assessed before and up to 4 weeks after&#xD;
      infusion. Adverse events will be recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reports have shown that intravenous lidocaine infusions have been effective in relieving&#xD;
      chronic pain that has been resistant to other therapies, with minimal side effects. The&#xD;
      investigators would like to determine whether severity of pain and degree of chronic-pain&#xD;
      related disability could be reduced with lidocaine infusion in children and to understand&#xD;
      whether the dose of lidocaine correlates with blood levels in the same manner as it does in&#xD;
      adults. The investigators will recruit 24 patients aged 8-18 with chronic pain that has not&#xD;
      been relieved by standard therapies. Each patient will receive a lidocaine infusion over 2&#xD;
      hours. Blood will be drawn for lidocaine concentration before the beginning of the infusion,&#xD;
      immediately after and 0.5, 2 and 4 hours after. Severity of pain and degree of disability&#xD;
      will be recorded using a questionnaire measuring pain scores, sleep disruption, social&#xD;
      disruption, physical abilities and school attendance before the infusion, weekly for 2 weeks&#xD;
      and then 4 weeks after. This study will help the investigators better understand the&#xD;
      effectiveness and safety of intravenous lidocaine for chronic pain in children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Change from baseline pain score (7 days prior to infusion) at 14 days after completion of infusion</time_frame>
    <description>Pain scores will be measured using the Numeric Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesic Requirement</measure>
    <time_frame>Up to seven days prior to lidocaine infusion.</time_frame>
    <description>Participants will record all analgesics used in a pain diary provided by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Requirement</measure>
    <time_frame>Up to one month after lidocaine infusion</time_frame>
    <description>Participants will record all analgesics used in a pain diary provided by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>intraoperative</time_frame>
    <description>Participants will be monitored for adverse events including cardiac arrhythmias, hypotension, hypertension, tachycardia, metallic taste, tinnitus, lightheadedness, nausea, vomiting and headache</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep</measure>
    <time_frame>Day of the infusion, one week, two weeks and four weeks following the infusion.</time_frame>
    <description>The Adolescent Sleep Wake Scale will be used to assess quantity and quality of sleep.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain Interference</measure>
    <time_frame>Day of the infusion, one week, two weeks and four weeks following infusion.</time_frame>
    <description>The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Scale will be used to measure how pain interferes with the participants activities of daily living</description>
  </other_outcome>
  <other_outcome>
    <measure>School Attendance</measure>
    <time_frame>Week prior to the infusion and at two and four weeks following the infusion.</time_frame>
    <description>Participants will record the number of hours of school attendance where relevant (e.g. no school holidays, no medical appointments).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pain, Chronic</condition>
  <arm_group>
    <arm_group_label>Lidocaine Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Infusion</intervention_name>
    <description>Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.</description>
    <arm_group_label>Lidocaine Infusion</arm_group_label>
    <other_name>Preservative Free Lidocaine Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with a chronic pain condition (&gt; 3 months) other conventional medical&#xD;
             therapies (anticonvulsants, tricyclics etc), have not been effective.&#xD;
&#xD;
          2. American Society of Anesthesiologists class 1 or 2&#xD;
&#xD;
          3. Age 8-18 years&#xD;
&#xD;
          4. Ability to understand and use the numeric rating scale to rate their pain and to&#xD;
             understand and answer other questionnaires&#xD;
&#xD;
          5. Negative pregnancy test in participants of child-bearing potential (Females 12 years&#xD;
             of age and older, or menarchal if under 12)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of seizures&#xD;
&#xD;
          2. Known liver or renal disease&#xD;
&#xD;
          3. Patient taking CYP1A2 substrate or inhibitors (eg. Ciprofloxacin, fluvoxamine,&#xD;
             clozapine, duloxetine, melatonin, propranolol, tizanidine)&#xD;
&#xD;
          4. Allergy or sensitivity to lidocaine or other local anesthetic&#xD;
&#xD;
          5. Cardiac conduction anomalies (eg. Heart block, Wolff-Parkinson-White)&#xD;
&#xD;
          6. Serum electrolytes (potassium, sodium, magnesium or calcium) outside of reference&#xD;
             ranges&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
        Withdrawal Criteria&#xD;
&#xD;
          1. Patient or parent/guardian request&#xD;
&#xD;
          2. Refusal to have intravenous access and serum levels drawn&#xD;
&#xD;
          3. Inability to complete pain scores on the questionnaires (paper or electronic) at the&#xD;
             first infusion and weekly for 2 weeks and at one month following infusion&#xD;
&#xD;
          4. Baseline free carnitine concentration &lt; 26 micromoles/L or total carnitine &lt; 32&#xD;
             micromoles/L (reference values from SickKids Department of Pediatric Laboratory&#xD;
             Medicine &quot;Guide to Laboratory Services&quot;)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Isaac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Isaac, MD</last_name>
    <phone>416-813-6410</phone>
    <email>lisa.isaac@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyne Pehora, RN</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>202406</phone_ext>
    <email>carolyne.pehora@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Isaac, MD</last_name>
      <phone>416-813-6410</phone>
      <email>lisa.isaac@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Carolyne Pehora, RN</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>202406</phone_ext>
      <email>carolyne.pehora@sickkids.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 15, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Lisa Isaac</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Anesthetics, Local</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

